Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067208 | 0.85 | GRM2 (0.48) | GRM2PTK2TDP1SLC9A1NPC1 | |
| SCHEMBL4322252 | 0.84 | PTK2 (0.51) | GRM2PTK2 | |
| SCHEMBL7599503 | 0.80 | SLC9A1 (0.69) | GRM2PTK2TDP1SLC9A1NPC1 | |
| SCHEMBL3800690 | 0.78 | HSD17B10 (0.56) | GRM2PTK2TDP1SLC9A1NPC1 | |
| SCHEMBL16016212 | 0.76 | TDP1 (0.62) | GRM2PTK2TDP1SLC9A1NPC1 | |
| SCHEMBL15906128 | 0.74 | HTT (0.50) | TDP1POLBKDM4E | |
| SCHEMBL22000732 | 0.73 | GRM2 (0.75) | GRM2PTK2TDP1SLC9A1NPC1 | |
| SCHEMBL15906155 | 0.72 | MAPT (0.46) | POLBKDM4E | |
| SCHEMBL15906086 | 0.72 | SMN1; SMN2 (0.45) | NPC1RAB9AKDM4E | |
| SCHEMBL15906170 | 0.72 | HTR2C (0.46) | NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | GRM2 1314/4885PTK2 1851/4885TDP1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.